Budesonide and nasal allergen challenge testing in man

In a nasal allergen challenge test, the effect of the glucocorticosteroid, Budesonide, on the pollen allergic type I reaction has been investigated. Placebo and two different dosages of budesonide were administered intranasally for 1 week before the challenge was performed. The study was designed as a double-blind cross-over trial. One week of treatment with the active steroid significantly reduced the nasal secretion compared to placebo as measured with the aid of a symptom score, and significantly reduced the induced nasal blockage measured objectively by means of rhinomanometry. No difference was found between the two dosages of budesonide, 400 micrograms and 100 micrograms daily, used in the study.